These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 15136228

  • 21. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

  • 22. Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML.
    Na IK, Kreuzer KA, Lupberger J, Dörken B, le Coutre P.
    Leuk Res; 2005 Mar; 29(3):343-5. PubMed ID: 15661271
    [Abstract] [Full Text] [Related]

  • 23. BCR-ABL positive essential thrombocythaemia: a variant of chronic myelogerous leukaemia or a distinct clinical entity: a special case report.
    Fadilah SA, Cheong SK.
    Singapore Med J; 2000 Dec; 41(12):595-8. PubMed ID: 11296785
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.
    Goh HG, Hwang JY, Kim SH, Lee YH, Kim YL, Kim DW.
    Transl Res; 2006 Nov; 148(5):249-56. PubMed ID: 17145570
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
    Moravcová J, Rulcová J, Polák J, Zemanová Z, Klamová H, Haskovec C.
    Leuk Res; 2005 Nov; 29(11):1365-6. PubMed ID: 15876454
    [No Abstract] [Full Text] [Related]

  • 29. CML with e6a2 BCR-ABL1 transcript: an aggressive entity?
    Beel KA, Lemmens J, Vranckx H, Maertens J, Vandenberghe P.
    Ann Hematol; 2011 Oct; 90(10):1241-3. PubMed ID: 21302112
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
    Roti G, La Starza R, Gorello P, Gottardi E, Crescenzi B, Martelli MF, Mecucci C.
    Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118
    [Abstract] [Full Text] [Related]

  • 32. HOXA9 gene expression in the chronic myeloid leukemia progression.
    Tedeschi FA, Zalazar FE.
    Leuk Res; 2006 Nov; 30(11):1453-6. PubMed ID: 16630659
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.
    Clin Cancer Res; 2005 May 01; 11(9):3425-32. PubMed ID: 15867244
    [Abstract] [Full Text] [Related]

  • 37. Minimal residual disease in chronic myeloid leukemia.
    Löwenberg B.
    N Engl J Med; 2003 Oct 09; 349(15):1399-401. PubMed ID: 14534331
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).
    Chomel JC, Sorel N, Bonnet ML, Bertrand A, Brizard F, Saulnier PJ, Roy L, Guilhot F, Turhan AG.
    Leuk Res; 2009 Apr 09; 33(4):551-5. PubMed ID: 18829107
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.